DHR vs. MTD: Danaher vs. Mettler-Toledo Stock Comparison
How do Danaher (DHR) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Danaher (DHR) and Mettler-Toledo (MTD) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | DHR | MTD |
|---|---|---|
| Name | Danaher Corp. | Mettler-Toledo International Inc. |
| Country/Region | United States | Switzerland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 161.86 billion USD | 34.25 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | December 29, 1978 | November 14, 1997 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | DHR | MTD |
|---|---|---|
| Total Return (1Y) | 11.88% | 21.58% |
| Total Return (3Y, Annualized) | 6.67% | 19.54% |
| Total Return (5Y, Annualized) | -2.05% | 2.36% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | DHR | MTD |
|---|---|---|
| Volatility (1Y, Annualized) | 30.61% | 31.70% |
| Beta (5Y) | 0.76 | 1.15 |
| Max Drawdown (5Y) | -43.31% | -43.47% |
| Avg. Volume (3M) | 3.94M | 197.80K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | DHR | MTD |
|---|---|---|
| Sharpe Ratio (1Y) | 0.25 | 0.55 |
| Sortino Ratio (1Y) | 0.35 | 0.75 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Danaher (DHR) earns 8.19% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 109.18%
- DHR
- 8.19%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
Net Margin (TTM)
Mettler-Toledo (MTD) at 22.25% keeps the most of each sales dollar — above its industry’s net margin range — and Danaher (DHR) at 16.91% also retains a top-quartile share.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.91%
- Max
- 18.05%
- DHR
- 16.91%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Danaher (DHR) at 21.13% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.13%
- Max
- 83.12%
- DHR
- 21.13%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | DHR | MTD |
|---|---|---|
| ROE (TTM) | 8.19% | -- |
| ROA (TTM) | 4.06% | 20.09% |
| Net Margin (TTM) | 16.91% | 22.25% |
| Operating Margin (TTM) | 21.13% | 28.70% |
| Gross Margin (TTM) | 59.36% | 59.16% |
Growth
Revenue Growth
Both Danaher (DHR) at 2.90% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Danaher (DHR) at -4.54% and Mettler-Toledo (MTD) at 3.88% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | DHR | MTD |
|---|---|---|
| Revenue Growth (YoY) | 2.90% | 3.98% |
| Revenue Growth (3Y CAGR) | -2.67% | 0.90% |
| EPS Growth (YoY) | -4.54% | 3.88% |
| EPS Growth (3Y CAGR) | -19.44% | 3.06% |
Financial Strength
Current Ratio (MRQ)
Both Danaher (DHR) at 1.63 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- DHR
- 1.63
- Min
- 0.10
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
Debt / Equity (MRQ)
Danaher (DHR) at 0.52 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.52
- Max
- 1.42
- Q3
- 0.65
- DHR
- 0.52
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | DHR | MTD |
|---|---|---|
| Current Ratio (MRQ) | 1.63 | 1.10 |
| Debt / Equity (MRQ) | 0.52 | 26.06 |
| Net Debt / EBITDA | 2.68 | 1.58 |
Dividends
Dividend Yield (TTM)
Mettler-Toledo (MTD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a yield of 0.67%, ranking against industry peers normally.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67%
- DHR
- 0.67%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Mettler-Toledo (MTD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Danaher (DHR) reports a payout of 25.17%, ranking against industry peers normally.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.17%
- DHR
- 25.17%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | DHR | MTD |
|---|---|---|
| Dividend Yield (TTM) | 0.67% | 0.00% |
| Dividend Payout Ratio (TTM) | 25.17% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Danaher (DHR) at 38.12 and Mettler-Toledo (MTD) at 37.38 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.12
- Max
- 85.34
- Q3
- 43.46
- DHR
- 38.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Danaher (DHR) at 6.32 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.32
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- DHR
- 6.32
- Q1
- 3.01
- Min
- 0.01
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Danaher (DHR) at 3.02 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.
DHR
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.02
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- DHR
- 3.02
- Q1
- 1.69
- Min
- -5.59
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | DHR | MTD |
|---|---|---|
| P/E Ratio (TTM) | 38.12 | 37.38 |
| P/S Ratio (TTM) | 6.32 | 8.16 |
| P/B Ratio (MRQ) | 3.02 | 442.71 |
| Free Cash Flow Yield (TTM) | 2.93% | 1.97% |